[Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
We assayed blood-plasma concentrations of insulin-like growth factor (IGF) and its protein--carrier of IGFBP3, total and free prostate-specific antigen (PSA). IGF levels in all groups of patients were higher than in controls. The highest concentrations were reported for benign hyperplasia of the prostate (BHP) with concomitant intraepithelial neoplasia (152.0 +/- 51.4 ng/ml) and in prostate cancer (119.2 +/- 32.2 ng/ml). According to Cox analysis results, BHP with concomitant intraepithelial neoplasia appeared to be an independent prognostic factor which influenced the period prior to tumor progression and outcome (p = 0.01). Blood-plasma concentration of IGF reliably correlated with the time elapsed prior to onset of prostatic tumor progression and serological recurrence of PSA within the first 12 months among patients with locally-advanced prostate cancer (Gleason's total > or = 7 before specialized treatment and blood-serum IGF > or = 99.2 ng/ml).